Aligning health insurance benefits with clinical goals, aka value-based insurance design (VBID), holds much promise for reducing financial barriers to recommended care, improving quality, and modulating spending growth. While studies have found that patient cost-sharing can reduce the use of necessary care and increase spending for downstream care such as hospitalizations, there have been few rigorous VBID studies, especially of the effects on overall clinical or spending outcomes. The Patient Protection and Affordable Care Act (ACA) requires that all Medicare beneficiaries have free access to preventive services starting in 2011, thus creating a VBID natural experiment. This elimination of cost-sharing has the potential to mitigate underuse of cancer screening tests recommended by the US Preventive Services Task Force (USPSF). Using information from large Medicare Advantage plans, this project will examine the clinical and economic effects of this ACA- mandated Medicare policy change. Our 2007-2014 data contain detailed, comprehensive information on insurance benefits, individual characteristics, testing, clinical events, and medical spending. The study sample includes beneficiaries with a range of pre-policy cost-sharing amounts with the staggered elimination of cost- sharing (free screening) over time. For example, 46% of the study population had free colorectal cancer screening in 2007, 74% in 2010, and 100% in 2011;all benefit changes occur on January 1st of the year. The three aims examine the cost-sharing changes'direct and overall effects:
Aim 1) screening test rates;
Aim 2) clinical event rates;
and Aim 3) total medical spending. We will evaluate the outcomes in all subjects and illustrative subgroups, e.g., subjects for whom screening may be of high or low value as per the USPSTF recommendations. Our primary analyses will focus on within-person changes (fixed effects estimation), and will adjust for a rich set of demographic, clinical, physician, and system characteristics. We also will compare subjects with cost-sharing versus those without cost-sharing, using as concurrent controls subjects who consistently have free screening throughout the study period. With several million person-years of data, we will have adequate power to detect even small changes in our outcomes. This study provides an opportunity to evaluate the largest VBID natural experiment to date, to examine the early effects of a major ACA provision on access to preventive care, and to inform future Medicare policy decisions.
This study will examine the effects of providing free cancer screening to Medicare beneficiaries, as required by the recent Patient Protection and Affordable Care Act. While free screening is intuitively appealing, there is limited evidence that eliminating patient cost-sharing will increase screening rates, controversy over the value of some types of screening, and considerable debate about the overall effects on medical spending. This work will inform Medicare and national health policy decisions and ongoing efforts to improve the quality and efficiency of care.
|Moura, Lidia M V R; Carneiro, Thiago S; Cole, Andrew J et al. (2016) Association between addressing antiseizure drug side effects and patient-reported medication adherence in epilepsy. Patient Prefer Adherence 10:2197-2207|
|GarcÃa-AlbÃ©niz, Xabier; Hsu, John; Lipsitch, Marc et al. (2016) Infective endocarditis and cancer in the elderly. Eur J Epidemiol 31:41-9|
|Ogbechie, Oluwatobi Awele; Hsu, John (2015) Systematic review of benefit designs with differential cost sharing for prescription drugs. Am J Manag Care 21:e338-48|